These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30242062)

  • 1. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
    Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
    Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
    Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
    Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.
    Khoramnia R; Peto T; Koch F; Taylor SR; Castro de Sousa JP; Hill L; Bailey C; Chakravarthy U;
    Br J Ophthalmol; 2023 Oct; 107(10):1502-1508. PubMed ID: 35840291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILUVIEN
    Teixeira C; Pessoa B; Ruão M; Sousa JPC; Penas S; Silva R; Carneiro Â; Meireles A
    Eur J Ophthalmol; 2024 Jul; 34(4):1149-1158. PubMed ID: 38013451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
    Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
    Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
    Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
    Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
    Holden SE; Currie CJ; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
    Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE;
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
    Currie CJ; Holden SE; Berni E; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results.
    Dobler E; Mohammed BR; Chavan R; Lip PL; Mitra A; Mushtaq B
    Eye (Lond); 2023 Aug; 37(11):2310-2315. PubMed ID: 36513858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
    Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
    BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
    Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
    Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
    Panos GD; Arruti N; Patra S
    Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.